Vaccine Development

Oct 04, 2017
By BioPharm International Editors
Under Project BioShield, the agency could provide more than $170 million in funding to purchase and support late-stage development of Ebola vaccines and therapeutic drugs.
Oct 04, 2017
By BioPharm International Editors
The Danish biotechnology company has been awarded a sole-source BARDA contract valued at more than $539 million for a freeze-dried smallpox vaccine.
Oct 02, 2017
By BioPharm International Editors
A grant from the Bill & Melinda Gates Foundation will advance PnuVax’s pneumonia vaccine’s clinical development and biomanufacturing scale-up using a low-cost manufacturing approach.
Sep 20, 2017
By BioPharm International Editors
Under this partnership, Johnson & Johnson and BARDA will focus on the advanced development of a small-molecule drug and vaccine for the pandemic flu.
Sep 15, 2017
BioPharm International
Using a hollow microstructured transdermal system to deliver a vaccine directly to the dermis.
Sep 14, 2017
By BioPharm International Editors
Shingrix represents a new, possibly better alternative to existing treatments.
Aug 28, 2017
By BioPharm International Editors
FDA halts unproved stem-cell cancer treatments administered to California patients, which was derived from a commercially unavailable military-grade vaccine.
Aug 28, 2017
By BioPharm International Editors
The acquisition of Protein Sciences, a vaccines biotechnology company, strengthens Sanofi’s influenza vaccines portfolio.
Aug 09, 2017
By BioPharm International Editors
Through its life-sciences business, MilliporeSigma, Merck KGaA will collaborate with Baylor College of Medicine to advance vaccine development for neglected and emerging diseases.
Aug 09, 2017
By BioPharm International Editors
FDA requests more detailed information on a post-marketing study for Dynavax’s hep-B vaccine, which will require an extended review time past its August 2017 PDUFA date.
native1_300x100
lorem ipsum